CJC-1295 / Ipamorelin Stack vs Ghrelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileGhrelin
Endogenous 28-amino acid peptide secreted primarily by the stomach that functions as both the primary hunger signal and a potent growth hormone secretagogue. The n-octanoyl modification at Ser-3 (acylated form) is required for GHS-R1a receptor binding and GH-stimulating activity. Understanding ghrelin explains the mechanism behind the entire GHRP class of research peptides.
Full profile| CJC-1295 / Ipamorelin Stack | Ghrelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | GHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelin |
| Evidence | FDA-approved | Investigational (in trials) |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Intravenous (research), Subcutaneous injection |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Appetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulation |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while Ghrelin is investigational (in trials).
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Ghrelin — Intravenous (research), Subcutaneous injection.
- Dosing units differ: CJC-1295 / Ipamorelin Stack is dosed in mcg, Ghrelin in mcg/kg — they operate at different scales.
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Ghrelin is IV or SC bolus; endogenous levels peak pre-meal.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
Ghrelin
Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.